IRIS
ALBANESE, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.204
AS - Asia 2.907
EU - Europa 2.040
Continente sconosciuto - Info sul continente non disponibili 403
SA - Sud America 350
AF - Africa 42
OC - Oceania 6
Totale 20.952
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.083
SG - Singapore 1.490
IT - Italia 678
CN - Cina 439
BD - Bangladesh 298
RU - Federazione Russa 298
BR - Brasile 283
DE - Germania 235
VN - Vietnam 190
HK - Hong Kong 181
UA - Ucraina 180
IE - Irlanda 139
FR - Francia 123
JP - Giappone 98
GB - Regno Unito 97
FI - Finlandia 75
CA - Canada 61
KR - Corea 61
PL - Polonia 61
NL - Olanda 36
SE - Svezia 36
IN - India 30
AR - Argentina 25
ID - Indonesia 19
ES - Italia 18
MX - Messico 18
ZA - Sudafrica 14
JM - Giamaica 13
CO - Colombia 12
EC - Ecuador 12
IQ - Iraq 12
TR - Turchia 11
BE - Belgio 10
UZ - Uzbekistan 10
AT - Austria 9
MA - Marocco 9
PK - Pakistan 9
CR - Costa Rica 8
PH - Filippine 8
AE - Emirati Arabi Uniti 7
IL - Israele 7
TN - Tunisia 7
AU - Australia 6
EG - Egitto 6
AL - Albania 5
EU - Europa 5
GR - Grecia 5
JO - Giordania 5
MY - Malesia 5
RS - Serbia 5
SA - Arabia Saudita 5
TW - Taiwan 5
CH - Svizzera 4
CL - Cile 4
CZ - Repubblica Ceca 4
KG - Kirghizistan 4
PY - Paraguay 4
VE - Venezuela 4
HN - Honduras 3
NI - Nicaragua 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BO - Bolivia 2
BY - Bielorussia 2
DZ - Algeria 2
GT - Guatemala 2
KE - Kenya 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
LV - Lettonia 2
PE - Perù 2
PR - Porto Rico 2
QA - Qatar 2
RO - Romania 2
SV - El Salvador 2
UY - Uruguay 2
VC - Saint Vincent e Grenadine 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BN - Brunei Darussalam 1
CM - Camerun 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KZ - Kazakistan 1
MD - Moldavia 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 20.554
Salva come PNG Salva come JPEG
Città #
Woodbridge 3.638
Wilmington 3.337
Houston 3.017
Singapore 565
San Jose 557
Fairfield 477
Ashburn 435
Council Bluffs 339
Ann Arbor 280
Chandler 220
Seattle 198
Cambridge 179
Hong Kong 179
Beijing 162
Rome 151
Jacksonville 148
New York 141
Dublin 136
Colorado Springs 111
Medford 102
Los Angeles 98
Tokyo 89
Santa Clara 88
The Dalles 85
Ho Chi Minh City 69
Milan 68
Buffalo 59
Lawrence 47
Moscow 46
Kraków 45
Hanoi 42
Lauterbourg 41
Dallas 38
Helsinki 34
Zhengzhou 34
Dearborn 32
São Paulo 32
San Diego 29
Atlanta 26
Naples 26
Menlo Park 25
Chicago 23
Norwalk 23
North Bergen 19
London 18
Nuremberg 18
Redwood City 18
Turin 17
Brooklyn 16
Phoenix 16
Toronto 16
Elk Grove Village 14
Philadelphia 14
Salt Lake City 14
Columbus 13
Frankfurt am Main 12
Jakarta 12
Boardman 11
Miami 11
Orem 11
Redondo Beach 11
Rio de Janeiro 11
San Francisco 11
Shanghai 11
Brussels 10
Charlotte 10
Tampa 10
Verona 10
Warsaw 10
Guangzhou 9
Johannesburg 9
Lappeenranta 9
Palermo 9
Boston 8
Haiphong 8
Manchester 8
Monte Vista 8
Newark 8
University Park 8
Washington 8
Amsterdam 7
Austin 7
Bologna 7
Denver 7
Florence 7
Munich 7
Tashkent 7
Belo Horizonte 6
Bogotá 6
Hefei 6
Kingston 6
Las Vegas 6
Madrid 6
Montreal 6
Palo Alto 6
Paris 6
Roebling 6
Seoul 6
Sterling 6
Stockholm 6
Totale 16.034
Salva come PNG Salva come JPEG
Nome #
Symptomatic nonconvulsive status epilepticus erroneously suggestive of sporadic Creutzfeldt-Jakob disease 631
Increased cortical excitability after selective REM sleep deprivation in healthy humans: a transcranial magnetic stimulation study 597
Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2 587
Unexpected total recovery in a patient with post-anoxic complete alpha coma predicted by recording of cortical SEPs 533
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 522
Chronic dopaminergic treatment in restless legs syndrome: Does it affect the autonomic nervous system? 512
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 510
Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study 495
Predicting seizures in untreated temporal lobe epilepsy using point-process nonlinear models of heartbeat dynamics 491
Effects of epilepsy treatment on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics 480
Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct Toll-like receptors 474
Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease 472
Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self-reported questionnaires 459
Unilateral spatial neglect and alien limb phenomenon may be early features of Creutzfeldt-Jakob disease 458
May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis 450
Pure ictal sensory seizures may represent a clinical manifestation of PLEDs 442
Facial diplegia resembling bilateral Ramsay Hunt Syndrome 439
Fronto-central monomorphic theta activity as EEG pattern of ictal psychosis 438
Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. 438
Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia 434
Sleep disorders in spinal and bulbar muscular atrophy (Kennedy's disease): a controlled polysomnographic and self-reported questionnaires study 424
Spasticity as an ictal pattern due to excitotoxic upper motor neuron damage 417
Restless legs syndrome and post polio syndrome: a case-control study 408
CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis? 405
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 401
May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy? 397
Multiple sleep latency test may be not sensitive in obstructive sleep apnea with comorbid narcolepsy revealed by low cerebrospinal fluid orexin levels 396
Nocturnal frontal lobe epilepsy with paroxysmal arousals due to CHRNA2 loss of function 396
Electroencephalography and dementia: a literature review and future perspectives 394
Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis 393
Epstein-Barr virus neuraxis infection as a trigger for central nervous system demyelinating processes: a case report 374
Sleep disorders in adult-onset myotonic dystrophy type 1: a controlled polysomnographic study 364
Sleep-wake cycle in the Kennedy's disease: a controlled polysomnographic study and self-reported questionnaires 359
Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson’s disease 329
Feasibility of automated detection of sleep apnea using implantable pacemakers and defibrillators: a comparison with simultaneous polysomnography recording 274
Heart rate variability in untreated newly diagnosed temporal lobe epilepsy: Evidence for ictal sympathetic dysregulation 267
Lower instantaneous entropy of heartbeat dynamics during seizures in untreated temporal lobe epilepsy 248
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 216
Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction 203
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study 194
Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case-Control Study 187
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 184
Functional assessment of outer and middle macular layers in multiple sclerosis 173
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis 130
Poor Adherence to the Mediterranean Diet and Sleep Disturbances Are Associated with Migraine Chronification and Disability among an Adult Population in the Lazio Region, Italy 121
GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures 118
Distortion product otoacoustic emissions and their suppression as predictors of peripheral auditory damage in migraine: a case-control study 113
Morphological Outer Retina Findings in Multiple Sclerosis Patients With or Without Optic Neuritis 110
Olfactory Dysfunction, Headache, and Mental Clouding in Adults with Long-COVID-19: What Is the Link between Cognition and Olfaction? A Cross-Sectional Study 108
Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients 106
Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction 96
Post-COVID-19 Hyposmia Does Not Exhibit Main Neurodegeneration Markers in the Olfactory Pathway 95
Fampridine improves acute optic neuritis contributing to a long-lasting recovery of nerve function 95
Correlation between endometriosis and migraine features: Results from a prospective case-control study 94
Subclinical cochlear dysfunction in newly diagnosed relapsing-remitting multiple sclerosis 94
Acupuncture Versus Standard Medical Care in the Prophylactic Treatment of Migraine: A Systematic Review and Meta-Analysis 93
Link between gut microbiota dysbiosis and chronic kidney disease 90
Inflammatory cytokine signatures are associated with disease burden and comorbidity of episodic migraine and endometriosis 80
One-month atogepant treatment induces rapid changes in delta-band functional connectivity in migraine: an HD-EEG study 79
Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study 73
A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II) 71
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography 70
Evaluation of the retinal vascular and structural changes in migraine patients treated with anti-CGRP monoclonal antibodies 66
Linking migraine to gut dysbiosis and chronic non-communicable diseases 66
REPLY to "Comment on Correlation between endometriosis and migraine features: Results from a prospective case-control study'': correlation between endometriosis and migraine features is not based on a broad strokes results 64
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study 63
Long-Term Treatment with the Calcitonin Gene-Related Peptide Receptor Antagonist Erenumab in CADASIL: Two Case Reports 60
Unexpected genomic architecture in a sporadic case of C1-INH Hereditary Angioedema: the hidden heritability 59
Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic Dystrophies 55
Gut-oriented interventions in patients with multiple sclerosis: fact or fiction? 54
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE) 54
Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment 53
Early effect of onabotulinumtoxinA on EEG-based functional connectivity in patients with chronic migraine: A pilot study 51
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study 51
Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study) 48
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x) 46
Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study 45
In Alzheimer's disease sleep impairment is correlated with cognitive decline, increased tau and decreased beta-amyloid CSF levels 42
Correlation between epileptiform activity and cerebrospinal fluid biomarkers in Alzheimer's disease 41
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ) 39
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance 39
Redefining migraine prevention: Early treatment with anti-CGRP monoclonal antibodies enhances response in the real world 38
Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study 38
Variable Ophthalmologic Phenotypes Associated with Biallelic Loss-of-Function Variants in POMGNT1 38
Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study) 38
Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study 36
Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review 35
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience 34
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients 34
Alzheimer disease: sleep, orexin and cognitive decline 33
Clinical Management of migraine 32
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study) 32
Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence 31
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study) 29
Medication overuse and drug addiction: a narrative review from addiction perspective 28
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study 28
Reward-Economic Choices-Decision Making and Dopamine 28
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) 27
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study) 27
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study 27
Totale 20.710
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.278
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.278
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022440 0 0 18 9 40 52 17 22 55 62 18 147
2022/2023665 67 53 51 83 50 136 77 52 54 10 17 15
2023/2024245 38 6 14 8 17 51 11 8 5 27 12 48
2024/20251.989 43 236 128 90 24 230 111 77 113 198 417 322
2025/20264.343 176 108 301 212 204 87 845 502 508 532 419 449
2026/2027815 325 242 248 0 0 0 0 0 0 0 0 0
Totale 20.952